FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO The anti-coagulant heparin reduces the likelihood of death from COVID-19 by 78% when administered in therapeutic doses to patients with signs of respiratory failure on admission to hospital, according to a study reported on October 14 in the British Medical Journal. The World Health Organization (WHO) currently recommends...